
Publication
Navigating international trade and tariffs
Recent tariffs and other trade measures have transformed the international trade landscape, impacting almost every sector, region and business worldwide.
Global | Publication | March 2017
On February 20, 2017, Health Canada released the Draft Guidance Document – Drug Facts Table for Non-prescription Drugs for comment. Interested stakeholders, including industry, consumers and healthcare professionals, may provide comments on the draft guidance document by email to nnhpd_consultation_dpsnso@hc-sc.gc.ca. The consultation period is open until April 21, 2017.
As part of Health Canada’s Plain Language Labelling Initiative (reported here), Health Canada released the Draft Guidance Document: Drug Facts Table for Non-prescription Drugs, which contains examples of drug facts tables for various active ingredients. The examples are intended to show the application of the specific formatting requirements for drug facts tables as set out in the Guidance Document: Good Label and Package Practices Guide for Non-prescription Drugs and Natural Health Products (GLPPG).
As part of the Plain Language Labelling Initiative, Health Canada will require that any new drug identification number (DIN) applications or supplemental new drug submissions submitted on and after June 13, 2017, comply with the drug facts table requirements set out in the GLPPG. In addition, currently marketed products must comply with the drug facts table requirements at the production level by June 20, 2019, and at the retail level by June 30, 2021.
The Plain Language Labelling Initiative imposes significant new obligations on industry. Interested stakeholders should consider whether the Draft Guidance – Drug Facts Table for Non-Prescription Drugs appropriately addresses the formatting requirements as set out in the GLPPG.
Draft Guidance Document: Drug Facts Table for Non-prescription Drugs
Publication
Recent tariffs and other trade measures have transformed the international trade landscape, impacting almost every sector, region and business worldwide.
Publication
Norton Rose Fulbright South Africa is acting on behalf of the Helen Suzman Foundation (HSF) in its application to be admitted as an amicus curiae in the ongoing High Court litigation regarding the state’s failure to prosecute apartheid-era crimes.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025